The David H. Koch Institute for Integrative Cancer Research at MITThe David H. Koch Institute for Integrative Cancer Research at MIT

Massachusetts Institute of Technology

National Cancer Institute Cancer Center

Science + Engineering... Conquering Cancer Together

SOLUTIONS with/in/sight:
Cancer Genetics and Precision Cancer Therapy

The Life Sciences Forum of the MIT Club of Northern California hosted the second Bay Area with/in/sight lecture from the David H. Koch Institute for Integrative Cancer Research at MIT on October 17, 2013. The program featured a series of informative talks about recent exciting progress in the areas of cancer genetics and new treatments based on our understanding of cancer genes, moderated by Prof. Laura D. Attardi, PhD, Associate Professor in the Departments of Radiation Oncology & Genetics at Stanford University School of Medicine. Presenters included:

  • Dr. Kevin Shannon, MD, Roma and Marvin Auerback Distinguished Professor in Pediatric Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center, discussed the challenges and opportunities of new cancer medicines from a clinical perspective.
  • Dr. Jeff Settleman, PhD, Senior Director of Discovery Oncology at Genentech, presented research from his own laboratory at Genentech as well as review new cancer therapeutic programs at the company.
  • Prof. Tyler Jacks, PhD, David H. Koch Professor of Biology, Investigator at the Howard Hughes Medical Institute, and Director of the Koch Institute for Integrative Cancer Research, discussed work from his laboratory on the development of novel therapeutic strategies that target common genetic alterations in many human cancers.

Watch the video below.

NOTE: On November 3, 2015, MIT TechTV suffered a loss of all video data, affecting the videos below. The KI web team is currently in conversation with MIT's Office of Digital Learning to determine whether or not this content can be recovered.  Apologies for the inconvenience and thank you for your patience.

Sponsorship for the event was provided by Bristol-Myers Squibb and Palo Alto Research Center.